Barbara Klencke, CMO at Sierra Oncology (now GSK) Shares Insights on the Significant benefits obtained from the Pivotal Myelofibrosis Study

Shots:Barbara gave a comprehensive view of the P-III (MOMENTUM) clinical study results which evaluates its lead candidate in myelofibrosisSierra is now acquired by GSK (completed on 1st July 2022) resulting in GSK commercializing this prime product once approvedThe interview outlines Sierra’s (now GSK) vision to develop transformative therapies for rare cancersSmriti: Thank…